/**/ RNS Number : 2234H IQ-AI Limited 02 May 2025 IQ-AI Ltd (“IQ-AI” or the “Company”) Imaging Biometrics Applies for FDA Breakthrough Therapy Designation May 2, 2025 – Imaging Biometrics, LLC (IB), a wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI), has today applied to the U.S. Food and Drug Administration for ‘Breakthrough
/**/ RNS Number : 2817G IQ-AI Limited 25 April 2025 IQ-AI Ltd (“IQ-AI” or “the Company”) Publication of Annual Report The Board of IQ-AI Ltd is pleased to announce the Company’s audited financial statements for the year ended 31 December 2024. The Annual Report will be available on the Company’s corporate website
/**/ RNS Number : 7655E IQ-AI Limited 11 April 2025 IQ-AI Ltd (“IQ-AI” or the “Company”) Imaging Biometrics Announces Promising Preliminary Results of Phase 1 Study Oral Gallium Maltolate Demonstrates Early Signals of Efficacy IQ-AI is pleased to provide the following update on its wholly-owned subsidiary, Imaging Biometrics LLC. The study on
/**/ RNS Number : 1361B IQ-AI Limited 18 March 2025 IQ-AI Ltd (“IQ-AI” or the “Company”) Placing to raise £250,000 IQ-AI is pleased to announce that that the Company, through its corporate broker Peterhouse Capital Limited (“Peterhouse”), has conditionally raised gross proceeds of £250,000 via a placing (the “Placing”) of 25,000,000 new
/**/ RNS Number : 5554V IQ-AI Limited 03 February 2025 February 3, 2025 Imaging Biometrics Expands Distribution with Blackford Imaging Biometrics, LLC (IB), Elm Grove, WI, a wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI), has amended their existing distribution agreement with AI platform provider Blackford Analysis Ltd (Blackford). The amendment adds
/**/ RNS Number : 1961U IQ-AI Limited 22 January 2025 IQ-AI Ltd (“IQ-AI” or the “Company”) Operations Update IQ-AI is pleased to announce an operations update. In this update, we focus on the relevance of artificial intelligence (“AI”) to our business, describe ongoing product development utilising AI in 2025, and provide an
/**/ RNS Number : 8964S IQ-AI Limited 10 January 2025 IQ-AI Ltd (“IQ-AI” or the “Company”) Imaging Biometrics and Prism Clinical Imaging Secure First Installation The combined technologies will enhance neurosurgical planning and treatment strategies Imaging Biometrics (IB), a wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI), is pleased
/**/ RNS Number : 8473M IQ-AI Limited 20 November 2024 November 20, 2024 IQ-AI Ltd (“IQ-AI” or the “Company”) Imaging Biometrics Expands Distribution Imaging Biometrics (IB), Elm Grove, WI, a wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI) has renewed its distribution agreement with GE HealthCare. This agreement aims to expand the distribution
/**/ RNS Number : 8206M IQ-AI Limited 19 November 2024 IQ-AI Ltd (“IQ-AI” or the “Company”) Board Changes IQ-AI Appoints Renowned Brain Tumor Champion to Board of Directors IQ-AI Ltd (LSE: IQAI) is pleased to announce the appointment of Dr. Al Musella, MD, as a Non-Execuitve Director. Dr. Musella brings